Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue,
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …

The consensus algorithm for the medical management of type 2 diabetes was published in
August 2006 with the expectation that it would be updated, based on the availability of new …

Background Data are lacking on the long-term effect on cardiovascular events of adding
sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and …

Moderate aLimited use in the US/Europe. bNot licensed in the US cPrescribing highly restricted
in the US; withdrawn in Europe. dNot licensed in Europe. eTo be available as a generic …

In 2012, the American Diabetes Association (ADA) and the European Association for the Study
of Diabetes (EASD) published a position statement on the management of hyperglycemia …

The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …

The epidemic of type 2 diabetes in the latter part of the 20th and in the early 21st century,
and the recognition that achieving specific glycemic goals can substantially reduce morbidity, …

Background The cardiovascular effects of adding once-weekly treatment with exenatide to
usual care in patients with type 2 diabetes are unknown. Methods We randomly assigned …

The American Heart Association (AHA) and the American Diabetes Association (ADA) have
each published guidelines for cardiovascular disease prevention: The ADA has issued …

Background Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor
agonists have a glucose-dependent action and promote weight loss. We compared the …